

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from 29TH March 2018**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Richard Harris – LPC Representative	✓
		Mr Andrew Houston - Senior Mental Health Pharmacist		Mr P Chatterton - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓			<u>DBTHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Mrs Heidi Atkinson- Non Medical Prescriber Representative (RDaSH DCIS)		Mr Andrew Barker – Chief Pharmacist DBTHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBTHFT	
Mr Rob Wise – Head of Medicines Management (BCCG)	✓	<u>Doncaster LMC</u>		Dr Lucy Peart – Acute Physician DBTHFT	✓
		Dr Dean Eggitt - LMC Secretary			
				<u>FCMS (When necessary)</u>	
		Dr Rumit Shah – LMC Chair	✓	Mrs Nicola Sanders Mrs Alison O’Conner Mrs Annie Armitage Mr Andrew Shakesby	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

Dr Rupert Suckling & Mr Victor Joseph DMBC

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Agenda Item	Discussion Points	Action By
03/18/1	Apologies Apologies were received from Dr D Eggitt, Mrs A Armitage	
03/18/2	Declarations of Interest, Gifts or Hospitality Mr R Wise declared that he has shares in Shire Pharmaceuticals (in relation to the ADHD item), The chair agreed for him to remain for discussions on this agenda item, as no final decision was being made today.	
03/18/3	Minutes of last meeting The minutes of the last meeting held on the 22 nd February 2018 were	

	agreed as a true and accurate record and will be made available on the medicines management website.	
03/18/4.1	<p>Matters Arising 02/18/8.1 Sheffield SCP for Epilepsy in Paediatrics NHSD- MMT (GB) will confirm that the existing pathway does accommodate the Paediatric Epilepsy Specialist Nurse supporting the titration for children in Doncaster.</p>	NHSD- MMT(GB)
11/15/8.4	<p>Shared Cared Protocol/Pathway update for the management of ADHD in adults, young people and Children The Committee received the draft SCP and a supporting document detailing the updates made to the paperwork. The recently published NICE guidance has been considered. Following discussion the following issues were raised by the Committee:</p> <ul style="list-style-type: none"> • LMC suggested that there should be some re-wording around the responsibility for monitoring patients and the course of action when there is a raised blood pressure • RDaSHFT to check why requests are being received in Primary Care to perform ECG's. • NHSB-MMT to check the position in Bassetlaw • DBTHFT to confirm that the paperwork will be supported • NHSD- MMT (GB) to share with the DCCG Medicines Management Committee <p>The potential re-classification of guanfacine & lisdexamfetamine dimesylate from red to amber will be considered via the horizon process at the next meeting. RDaSHFT agreed to make the changes to the document and present at the next meeting for possible sign off.</p>	<p>RDaSHFT</p> <p>NHSB- MMT</p> <p>DBTHFT</p> <p>NHSD- MMT(GB)</p>
10/16/8.2	<p>Parkinson's disease – Joint Shared Care Protocol The APC has agreed to support the development of a South Yorkshire and Bassetlaw protocol. The Committee was asked to comment on the current Barnsley CCG document as a starting point. This document has been recently agreed by the neurologists at Sheffield. The Committee agreed to using this document and suggested opinions should be sought from</p> <ul style="list-style-type: none"> • Dr Oates local Consultant Geriatrician • Parkinson's Disease Specialist Nurse <p>NHSD- MMT (GB) will advise Sheffield that the Committee would prefer to have a Proforma to accompany the SCP document to confirm agreement between parties and for ease of identifying any monitoring arrangements. The Committee also asked for clarity around LFT monitoring when using Tolcapone. Further updates will be shared at the next meeting.</p>	<p>NHSD- MMT(GB)</p> <p>DBTHFT</p> <p>RDaSHFT</p>
10/17/8.1	<p>FreeStyle Libre Glucose Monitoring System There has been no Business Case submitted from DBTHFT to support the use of this system thus far. The Committee are in agreement that the current Grey traffic light status should remain in place, Sheffield CCG is aware of this decision.</p>	

11/17/19.2	<p>Methotrexate injections –change from Red to Amber on TLS The meeting planned with NHSD-MMT, DBTHFT and LPC has now taken place. A pathway has been suggested and there are on-going discussions to finalise issues.</p>	NHSD-MMT(GB)
03/18/5	<p>Traffic Light – Drugs for Review All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Fluticasone/umeclidinium/ vilanterol (Trelegy) used in COPD has been categorised as Green-G Paclitaxel (Taxol) used to treat pancreatic cancer has been re-categorised from Grey to Red 1 Strontium ranelate (Protelos) used in osteoporosis has now been discontinued and the entry will be removed from the TLS. Ulipristal acetate (Esmya) used for uterine fibroids has been changed from Red to Grey 1 Liraglutide (Saxenda) used in weight management has been remains as Green-G All Gluten Free Products other than bread and bread mix have been categorised as Grey. Liothyronine sodium tabs used in Hypothyroidism (Amber-G) was discussed around further guidance to be added to the website. It was agreed that the comments at present are adequate.</p>	NHSD-MMT(AM)
03/18/6	<p>APC Officers actions All officers actions were agreed as proposed, will be updated on the traffic light system.</p>	NHSD-MMT(AM)
03/18/7	<p>Traffic Light – Additions for Consideration All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Tramadol /Dexketoprofen (Skudexa) used for pain has been categorised as Grey 4 until discussed at the FLG. Botulinum toxin type A (Vistabel) used for the temporary treatment of facial lines has been categorised as Grey 1 Tivozanib (Fotivda) used to treat renal cell carcinoma has been categorised as Red 1,2,3 Oral rehydration Salts (Glucodrate) used in the dietary management of short bowel-associated intestinal failure and intestinal insufficiency has been categorised as Red 1 Hydrocortisone (Alkindi) used in adrenal insufficiency in infants, children and adolescents has been categorised as Red 1,2 Emicizumab (Hemlibra) used in haemophilia A has been categorised as Red 1,2,3</p>	NHSD-MMT(AM)
03/18/8	<p>New Business</p>	
03/18/8.1	<p>Review of Red drug prescribing in Primary Care A further selection of Red drugs was presented to the Committee. All drugs below have been prescribed in Primary Care, the Committee agreed to a reminder being added to the T@blet around the Red categorisation.</p>	NHSD-MMT(AM)

	<ul style="list-style-type: none"> Aluminium Hydroxide used to treat Hyperphosphataemia Bromfenac used in ocular inflammation following cataract extraction in adults Calcium acetate used to treat Hyperphosphataemia Sodium dihydrogen phosphate dihydrate/Disodium phosphate dodecahydrate used for bowel cleansing prior to bowel endoscopy, radiology, or colonic surgery <p>There has also been one prescription for clozapine. RDaSHFT asked that the prescription is requested from the PPA in order to clarify the circumstances around this issue.</p>	
03/18/8.2	<p>Process for the prescribing and dispensing of Fidaxomicin in the management of Clostridium difficile</p> <p>The Committee agreed that the present document remains current. The review date will be updated. All Committee members are reminded to share the process within their organisations.</p>	NHSD-MMT(AM)
03/18/8.3	<p>SCP for Management of Inflammatory Arthritis, Connective Tissue Disease & Systemic Vasculitis for Adult services (over 16)</p> <p>The Committee was made aware of clinical guidance published by The Royal College of Ophthalmologists. The guidance includes details of additional monitoring required when hydroxychloroquine is used.</p> <p>The agreed action was for DBTHFT to cross reference the existing SCP paperwork with this guidance and amend where necessary. The Committee also requested that consideration should be given as to removing the mention of methotrexate 10mg tablets in the protocol and recommend the 2.5mg tablets use only. The rationale for this is to reduce the risk of prescribing and dispensing errors.</p> <p>The paperwork will return to the Committee for approval once changes are made.</p>	DBTHFT
03/18/8.4	<p>Responsibility for prescribing between Primary & Secondary/Tertiary Care</p> <p>NHS England has published a document detailing the responsibility for prescribing between Primary & Secondary/Tertiary Care. The document was received by the Committee. It was acknowledged that the document closely reflects the current position in Doncaster and Bassetlaw well.</p>	
03/18/8.5	<p>Shared Care Guidance for the treatment of Adults with Growth Hormone (Somatropin)</p> <p>The Sheffield paperwork was presented at the meeting. Sheffield CCG is happy to develop the document into a joint South Yorkshire and Bassetlaw protocol. The Committee asked that there was more detail around the re-referral guidelines. NHSD-MMT will feed this back via the SY&B Heads of Medicines Management meeting.</p>	NHSD-MMT(GB)
03/18/9	<p>DBTHFT D&TC Update</p> <p>No minutes available</p>	
03/18/10	<p>Formulary Liaison Group Update</p> <p>The minutes of the meeting held in January 2018 were received by</p>	

	the Committee	
03/18/11	Doncaster Prisons Drug & Therapeutic Committee No minutes available	
03/18/12	RDaSH FT & Medicines Management Committee Update The minutes of the meeting held in October, November, December 2017 and January, February 2018 were received by the Committee	
03/18/13	Barnsley Area Prescribing Committee Update No minutes available	
03/18/14	Rotherham Medicines Optimisation Group (RMOG) update The minutes of the meeting held in October, November, December 2017 were received by the Committee	
03/18/15	Sheffield Area Prescribing Committee Update The minutes of the meeting held in January 2018 were received by the Committee	
03/18/16	Nottinghamshire Area Prescribing Committee Update No minutes available	
03/18/17	SY& B Accountable Care System Medicines Optimisation Work-stream Steering Group The minutes of the meeting held in January 2018 were received by the Committee	
03/18/18	Northern Regional Medicines Optimisation Committee No minutes available	
03/18/19	Any Other Business The Committee was advised of a shortage of 100mg hydrocortisone injections. A GP Practice had asked that their current supply held in their emergency box was due to expire and replacements were not available. The Committee suggested that the individual surgery may want to review their emergency drug box policy as this medication is not routinely included.	LPC
03/18/20	Date, time & venue of next meeting 12 noon prompt Thursday 26th April 2018 in Meeting Room 3 Sovereign House	
	12 noon prompt Thursday 31st May 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 28th June 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 26th July 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 30th August 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 27th September 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 25th October 2018	

